RNA and DNA synthesis machinery

The RNA and DNA synthesis machinery is a comprehensive network of enzymes and proteins, including DNA polymerases, RNA polymerases, helicases, and topoisomerases, that facilitate genome replication and gene expression [1][2]. This machinery is essential for cell division and the life cycles of viral and bacterial pathogens, making it a cornerstone of pharmacological intervention in oncology and infectious diseases [3]. Therapeutic agents targeting this system include antimetabolites like methotrexate, which inhibit nucleotide precursor synthesis, and nucleoside analogs like acyclovir or gemcitabine, which incorporate into nascent strands to cause chain termination [4][5]. Additionally, inhibitors of topoisomerases, such as etoposide or ciprofloxacin, disrupt the management of DNA supercoiling during synthesis, leading to lethal DNA damage [6]. While highly effective, these drugs often exhibit narrow therapeutic indices due to their impact on healthy, rapidly proliferating host cells, resulting in common toxicities like myelosuppression and mucositis [7]. Consequently, the machinery remains a primary focus for developing more selective inhibitors that can distinguish between host and pathogen or malignant and normal cell processes [8].

Other names

Nucleic acid synthesis machineryDNA and RNA replication and transcription apparatusNucleic acid polymerasesReplication machinery

Inhibition of DNA/RNA polymerases, competitive inhibition of nucleotide synthesis, induction of DNA strand breaks via topoisomerase poisoning, and premature chain termination through nucleoside analog incorporation.